Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
about
Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathwaysReceptor tyrosine kinases in the nucleusProteolytic Processing of ErbB4 in Breast CancerNuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.Γ-secretase components as predictors of breast cancer outcomeThe ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epitheliumThe localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.Prognostic value of ERBB4 expression in patients with triple negative breast cancerProtein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical featuresHER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.Slow down to stay alive: HER4 protects against cellular stress and confers chemoresistance in neuroblastomaHuman epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression
P2860
Q24300478-A646ACAF-DD21-4EE6-BE8E-4D85097526C9Q26830216-131C1321-A6CB-4B9D-B208-D7EB02EE2E1EQ27670640-777328B6-FFD8-4D93-8078-25A3EB67DDE1Q27853060-72727A8C-0FB6-4965-B679-D0E6E9D8571EQ28534781-7792A9B3-1412-4545-B627-D7F8737BE12CQ33951695-0DDDE5C4-B970-4041-9196-2FC67F9830E7Q33977133-B4A5498E-0EDB-4DB7-B4FA-8F9921F6412EQ34428718-046433A5-54B5-4037-A020-EBD5502C1F4EQ34506613-60E927DA-669F-4FC5-8E36-B3F2D567A5CCQ34996222-24E198FA-467E-4C63-BDB6-CD655089E1E4Q35000695-3559E355-20CE-4287-B464-500E806E81C9Q35933318-297ADF1B-E1CB-4F17-9E11-DFF7F59C8E9EQ36080448-05BC7F82-D34E-4652-B973-97198CCD5695Q36113481-D4FD22E7-8FB3-4A7D-82F4-566D37D7FCD6Q36288449-71982206-0763-4873-A081-1B077EBDEF7CQ36914825-ED3A935E-FBC9-473A-AE0B-054080A3AB10Q37381593-9A5BE15B-BFBC-435E-87C4-0031F1D16732Q37718269-A33A3BA3-1081-47A8-857C-065A568A9A38Q37727542-A34A60D5-3825-4CA6-81BA-42732C4A09A8Q38890318-A4E341E5-09D7-4466-8C42-071F0EDDF188Q38971615-12B7BEEE-C491-4CDB-9F1D-461CD0FBB768Q39380224-292CF951-F471-4504-B1A8-56D46A62D18EQ45358927-1AACCABC-E277-4198-B3E4-13AF9A08BB87Q47158524-DEEACFCB-4B81-4D3F-865D-E3B5055C2548Q54339123-C4EC22FB-97EC-4DD5-9FFF-C394D8BE9EE7Q56968081-EB698608-9BD1-462F-97DB-FFFFFEA739EE
P2860
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Subcellular localization of th ...... es for breast cancer patients.
@en
Subcellular localization of th ...... es for breast cancer patients.
@nl
type
label
Subcellular localization of th ...... es for breast cancer patients.
@en
Subcellular localization of th ...... es for breast cancer patients.
@nl
prefLabel
Subcellular localization of th ...... es for breast cancer patients.
@en
Subcellular localization of th ...... es for breast cancer patients.
@nl
P2093
P2860
P1476
Subcellular localization of th ...... es for breast cancer patients.
@en
P2093
Ann D Thor
Frank E Jones
Susan M Edgerton
P2860
P304
P356
10.2353/AJPATH.2009.090204
P407
P577
2009-10-01T00:00:00Z